Systemic therapy for advanced hepatocellular carcinoma: Past, present, and future

Cancer Control

Volumn 17, Issue 2, 2010, Pages 120-129

  Giglia, Jennifer L ^a   Antonia, Scott J ^a   Berk, Lawrence B ^a   Bruno, Salvador ^a   Dessureault, Sophie ^a   Finkelstein, Steven E ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GEMCITABINE; INTERFERON; INTERLEUKIN 2; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NOLATREXED; OXALIPLATIN; PLACEBO; RAPAMYCIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SOMATOSTATIN; SORAFENIB; SUNITINIB; TAMOXIFEN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; ASTHENIA; BLEEDING; BLOOD TOXICITY; BRAIN DISEASE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DENDRITIC CELL; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EFFECTOR CELL; ESOPHAGUS VARICES BLEEDING; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOKALEMIA; INTESTINE PERFORATION; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; LYMPHOKINE ACTIVATED KILLER CELL; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; RASH; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT;

EID: 77952345360     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481001700207     Document Type: Article

References (93)

1. Bosch FX, Ribes J, Díaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 suppl 1):S5-S16.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485-1491.
3. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10): 698-711.
4. Thomas MB. Systemic therapy for hepatocellular carcinoma. Cancer J. 2008;14(2):123-127.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-216.
6. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41(4):707-716.
7. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The Liver and Portal Hypertension. Philadelphia, PA: Saunders; 1964.
8. Olweny CL, Toya T, Katongole-Mbidde E, et al. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer. 1975;36(4):1250-1257.
9. Sciarrino E, Cottone M, Dardanoni G, et al. Ultrasound in monitoring patients with hepatocellular carcinoma treated with adriamycin. Ann Radiol (Paris). 1985;28(1):21-24.
10. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, et al. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep. 1984;68(3):487-491.
11. Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer. 1988;62(3):479-483.
12. Mathurin P, Rixe O, Carbonell N, et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma: an impossible meta-analysis? Aliment Pharmacol Ther. 1998;12(2):111-126.
13. Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007;25(21): 3069-3075.
14. Hochster HS, Green MD, Speyer J, et al. 4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol. 1985;3(11):1535-1540.
15. Halm U, Etzrodt G, Schiefke I, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol. 2000;11(1):113-114.
16. Pohl J, Zuna I, Stremmel W, et al. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy. 2001;47(5):359-365.
17. Hong RL, Tseng YL. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2003;51(5):433-438.
18. Porta C, Moroni M, Nastasi G, et al. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology. 1995;52(6):487-491.
19. Link JS, Bateman JR, Paroly WS, et al. 5-Flourouracil in hepatocellular carcinoma: report of twenty-one cases. Cancer. 1977;39(5):1936-1939.
20. Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004;101(3):578-586.
21. Jiang W, Lu Z, He Y, Diasio RB. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res. 1997;3(3):395-399.
22. Matsumoto K, Nagahara T, Okano J, et al. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep. 2008;20(4):863-872.
23. Yang TS, Lin YC, Chen JS, et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2000;89(4):750-756.
24. Kubicka S, Rudolph KL, Tietze MK, et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001;48(39):783-789.
25. Fuchs CS, Clark JW, Ryan DP, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2002;94(12): 3186-3191.
26. Guan Z, Wang Y, Maoleekoonpairoj S, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer. 2003;89(10):1865-1869.
27. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007;109(7):1384-1390.
28. Taïeb J, Bonyhay L, Golli L, et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer. 2003;98(12):2664-2670.
29. O'Reilly EM, Stuart KE, Sanz-Altamira PM, et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer. 2001;91(1):101-105.
30. Boige V, Taïeb J, Hebbar M, et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer. 2006;42(4):456-459.
31. Castells A, Bruix J, Brú C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology. 1995;109(3):917-922.
32. Liu CL, Fan ST, Ng IO, et al. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol. 2000;95 (1):218-222.
33. Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 2002;36(5):1221-1226.
34. Nowak A, Findlay M, Culjak G, et al. Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev. 2004;(3):CD001024.
35. Becker G, Allgaier HP, Olschewski M, et al. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology. 2007;45(1):9-15.
36. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48(4):1312-1327.
37. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24 (26):4293-4300.
38. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
39. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.
40. Abou-Alfa GK, Johnson P, Knox J, et al. Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). Presented at the 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. 2008:128. Abstract.
41. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26(18):2992-2998.
42. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27(6):843-850.
43. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23(27):6657-6663.
44. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110(5): 1059-1067.
45. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007; 110(3):581-589.
46. Faivre S, Raymond E, Douillard J, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2007;25(suppl):18s. Abstract 3546.
47. Zhu AX, Sahani DV, di Tomaso E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2007 ASCO Ann Meet Proc (Post-Meet Ed). 2007;25(18S June 20 suppl):4637. Abstract.
48. Decaens T, Luciani A, Itti E. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma. Presented at the 2009 Gastrointestinal Cancers Symposium; January 15-17, 2009; San Francis-co, CA. 2009:244. Abstract.
49. Ferrero S, Ragni N. Prognostic value of plasma and serum VEGF levels in patients with resectable hepatocellular carcinoma. Ann Surg Oncol. 2003;10(9):1123.
50. Tseng PL, Tai MH, Huang CC, et al. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol. 2008;98(5): 349-357.
51. Feng DY, Zheng H, Tan Y, et al. Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol. 2001;7(1):33-36.
52. Huynh H, Nguyen TT, Chow KH, et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003;3:19.
53. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24): 11851-11858.
54. Abou-Alfa GK. Selection of patients with hepatocellular carcinoma for sorafenib. J Natl Compr Canc Netw. 2009;7(4):397-403.
55. Bolondi L, Caspary W, Bennouna J, et al. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial. Presented at the 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. 2008:129. Abstract.
56. Abou-Alfa GK, Amadori D, Santoro A, et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol. 2008;26(May 20 suppl):4518. Abstract.
57. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009;115(2):428-436.
58. Zhu A, Sahani D, di Tomaso E, et al. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): insights from a multidisciplinary phase II study. J Clin Oncol. 2008;26(May 20 suppl):4521. Abstract.
59. Hoda D, Catherine C, Strosberg J, et al. Phase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC). Presented at the 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. 2008:267. Abstract.
60. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(12):1898-1903
61. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 2008;112(12):2733-2739.
62. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6(9):729-734.
63. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972-1983, 1983.e1-11.
64. Wang Z, Zhou J, Fan J, et al. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135(5):715-722.
65. Tam KH, Yang ZF, Lau CK, et al. Inhibition of mTOR enhances chemo sensitivity in hepatocellular carcinoma. Cancer Lett. 2009;273(2): 201-209.
66. Piguet AC, Semela D, Keogh A, et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol. 2008;49(1):78-87.
67. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198(4):569-580.
68. Restifo NP, Antony PA, Finkelstein SE, et al. Assumptions of the tumor "escape" hypothesis. Semin Cancer Biol. 2002;12(1):81-86.
69. Lou Y, Wang G, Lizée G, et al. Dendritic cells strongly boost the anti-tumor activity of adoptively transferred T cells in vivo. Cancer Res. 2004;64(18):6783-6790.
70. Nagorsen D, Panelli M, Dudley ME, et al. Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells. Gene Ther. 2003;10(20):1754-1765.
71. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907-912.
72. Zeng R, Spolski R, Finkelstein SE, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med. 2005;201(1): 139-148.
73. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology. 1993;17(3):389-394.
74. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000;31(1):54-58.
75. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res. 1999;5(7):1676-1681.
76. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97(20):1532-1538.
77. Lygidakis NJ, Kosmidis P, Ziras N, et al. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res. 1995;15(5):467-472.
78. Reinisch W, Holub M, Katz A, et al. Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma. J Immunother. 2002;25(6):489-499.
79. Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol. 2004;22(8):1389-1397.
80. Une Y, Kawata A, Uchino J. Adopted immunochemotherapy using IL-2 and spleen LAK cell-randomized study [in Japanese]. Nippon Geka Gakkai Zasshi. 1991;92(9):1330-1333.
81. Kawata A, Une Y, Hosokawa M, et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients: Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol. 1995;18(3):257-262.
82. Wang Y, Chen H, Wu M, et al. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes. Chin Med J (Engl). 1997;110(2):114-117.
83. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356(9232):802-807.
84. Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol. 2004;10(8):1146-1151.
85. Ladhams A, Schmidt C, Sing G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol. 2002;17(8):889-896.
86. Iwashita Y, Tahara K, Goto S, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother. 2003;52(3):155-161.
87. Stift A, Friedl J, Dubsky P, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol. 2003;21(1):135-142.
88. Lee WC, Wang HC, Hung CF, et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother. 2005;28(5):496-504.
89. Chi KH, Liu SJ, Li CP, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother. 2005;28(2):129-135.
90. Palmer DC, Chan CC, Gattinoni L, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A. 2008;105(23):8061-8066.
91. Finkelstein SE, Fernandez FG, Dehdashti F, et al. Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. J Hepatobiliary Pancreat Surg. 2008;15(5):483-487.
92. Hoffe SE, Finkelstein SE, Russell MS, et al. Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer Control. 2010;17(2):100-110.
93. Finkelstein SE, Heimann DM, Klebanoff CA, et al. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol. 2004;76(2):333-337.